Related Experiment Video
Updated: Jan 6, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.0K
Systemic Interactions in HFpEF: A Multiorgan Perspective on Pathways and Therapeutic Targets.
Xinxin Cui1,2, Yuxin Hu2, Yunwei Xu2
1Cardiac Regeneration and Ageing Lab, Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong) and School of Life Science, Shanghai University, Nantong, 226011, China.
Journal of Cardiovascular Translational Research
|September 22, 2025
Summary
Heart failure with preserved ejection fraction (HFpEF) is a complex condition affecting multiple organs. This review explores HFpEF
Area of Science:
- Cardiology
- Metabolic Syndrome
- Multisystem Diseases
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a growing concern in aging and metabolically compromised individuals.
- HFpEF involves diastolic dysfunction, metabolic issues, inflammation, and oxidative stress impacting multiple organs.
- Interorgan communication is crucial in HFpEF progression.
Purpose of the Study:
- To review the multisystem pathophysiology of HFpEF from an interorgan perspective.
- To discuss current treatment limitations and future therapeutic strategies.
- To highlight the need for individualized, mechanism-based treatments for HFpEF.
Main Methods:
- Literature review focusing on HFpEF pathophysiology.
- Analysis of interorgan crosstalk in HFpEF.
- Synthesis of current and future therapeutic approaches.
Main Results:
- HFpEF is characterized by intrinsic cardiac issues and abnormalities in the kidneys, liver, lungs, adipose tissue, and skeletal muscle.
- Endothelial dysfunction and regional adiposity contribute to HFpEF.
- Current treatments show limited broad efficacy, necessitating novel strategies.
Conclusions:
- A comprehensive, multi-organ approach is essential for understanding and managing HFpEF.
- Future therapies should focus on interorgan integration and personalized medicine.
- Individualized, mechanism-based treatments hold promise for precision management of HFpEF.
Related Concept Videos
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:22Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228
01:27Heart Failure I: Introduction
653
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
653